A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project.

Daniel BarthelmesVuong NguyenRichard WaltonMark C GilliesVincent Daiennull null

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2018)

A similar rate of use for ranibizumab and aflibercept among Australian practitioners was observed between 2013 and 2016. Ranibizumab was used more often in older patients while aflibercept tended to be used more often in eyes with larger lesions.

Keyphrases

age related macular degeneration
diabetic retinopathy
optical coherence tomography
primary care
quality improvement
optic nerve